European multicentre study – first expectations fulfilled
An innovative treatment for drug-refractory epilepsy is being tested in a European multicentre study.
Press Release (ePRNews.com) - Heidelberg, Germany - Dec 10, 2019 - The pathway to a correct diagnosis in epilepsy patients is often very long. Furthermore, approx. 30% of all patients with epilepsy cannot be treated adequately in spite of a variety of medicinal options. The use of technical options for treatment plays an important role, particularly for these so-called drug-refractory patients. The novel stimulation method, EASEE®, is currently being tested by the Freiburg epileptologist Prof. Dr Andreas Schulze-Bonhage, to scientifically assess the opportunity for better control of epilepsy. Initial trends confirm the expectation that transcranial brain stimulation may constitute a new therapeutic option for focal epilepsy.
Patients with epilepsy are regarded as drug-refractory if their seizures cannot be fully controlled with tablets, i.e. if further events occur in spite of treatment with two standard preparations for the relevant form of seizures or epilepsy. Precisely for these patients, with focal inoperable epilepsy, the highly innovative neurostimulation method EASEE® could provide an opportunity of reducing the seizures and having a favourable effect on the course of the disease.
To this end, a thin silicone mat with integrated plate electrodes is positioned under the scalp using a minimally invasive procedure, directly over the epileptic centre. The bony cranium remains fully intact. Implantation of EASEE® only takes a few minutes. Two complementary electric signals are combined for an optimum treatment effect – alternating current stimulation and slightly modified direct current stimulation. The therapeutic impulses can be individually tailored to each patient.
EASEE® II study: first expectations of neurologists are confirmed
After the initial tests with EASEE® had demonstrated good tolerability, the European study, the EASEE® II study, was started in spring 2019 at five epilepsy centres. “In the current study, we are investigating whether EASEE® can be used as an innovative method to contribute towards better control of seizures and improving quality of life,” explains Prof. Dr Andreas Schulze-Bonhage, Medical Director of the Epilepsy Centre at the University Hospital of Freiburg. Initial data show that the electrodes are easily implanted under the scalp and are well tolerated by the patients. Long-term treatment and monitoring is required to meaningfully assess any reduction in the frequency or severity of seizures. “Our expectations in relation to the potential of the new stimulation method are currently being confirmed,” states the expert.
About Precisis AG
Precisis AG was founded in 2004 and is a company that specialises in the development of innovative medical devices, with its headquarters in Heidelberg.
Precisis AG is a byword for outstanding success in the field of instrument-controlled therapies for the brain. We are committed to progress and are developing individually tailored, precise treatment methods in the field of neurostimulation, to improve the lives of seriously ill patients. Ethical considerations and responsible handling of the complex technical options are naturally deeply rooted in the approach taken by our staff. Reliable solutions for people with functional brain disorders are hereby being developed in collaboration with strong partners.
EASEE® is an acronym for “Epicranial Application of Stimulation Electrodes for the treatment of Epilepsy”.
For further information on the activities, progress and milestones achieved by Precisis AG, please refer to the web page: www.precisis.de
Phone: +49 6221 6559300
WEFRA LIFE SOLUTIONS GmbH
Mitteldicker Weg 1 – WEFRA-Haus
63263 Neu-Isenburg – OT Zeppelinheim
Phone: +49 69 695008-557
Source : Precisis AG press release online version